Business Context and Reporting Period
Company: Senti Biosciences, Inc. (SNTI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Senti is a clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies. The company's lead product candidate, SENTI-202, is a Logic Gated off-the-shelf CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including Acute Myeloid Leukemia (AML). SENTI-202 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $22 | $0 |
| Net Loss | $(61,438) | $(52,790) |
| Research & Development Expenses | $37,586 | $34,356 |
| General & Administrative Expenses | $26,163 | $26,370 |
| Impairment of Long-Lived Assets | $5,052 | $313 |
| Cash and Cash Equivalents (Year End) | $16,420 | $48,277 |
| Accumulated Deficit | $(358,572) | $(297,134) |
| Net Cash Used in Operating Activities | $(43,444) | $(41,397) |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $8.6 million (16.4%) year-over-year, driven primarily by higher R&D expenses and a significant impairment charge.
- Impairment Charge: Recognized a $5.1 million impairment charge related to long-lived assets associated with the Alameda facility sublease due to the sublessee's (GeneFab) failure to remit payments.
- Revenue Recognition: Recognized $22,000 in collaboration revenue from BlueRock Therapeutics, compared to zero in the prior year.
- Cash Position: Cash and cash equivalents decreased by approximately $31.9 million, reflecting continued operating losses and capital expenditures.
- Equity Transactions: Converted 21,157 shares of Series A redeemable convertible preferred stock into 21,157,000 shares of common stock in March 2025. Raised approximately $10.6 million in net proceeds via an At-The-Market (ATM) offering program.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for 12 months following the issuance of the financial statements. Based on current operating plans and cash balances ($16.4 million), the company may not be able to maintain operations beyond the second quarter of 2026 without additional financing.
Material Risks and Contingencies
- GeneFab Sublease Default: As of December 31, 2025, GeneFab was in default on sublease payments for the Alameda facility. In March 2026 (subsequent event), the company entered into amendments to cure the default, reducing leased space and restructuring payments, with GeneFab agreeing to provide prepaid manufacturing credits for past-due rent.
- Celest Therapeutics Trial Halt: In April 2025, partner Celest Therapeutics ceased enrollment in the SN301A clinical trial in China due to dose-limiting toxicities. The company does not anticipate Celest will exercise its option to license the technology.
- Internal Controls: The company previously identified a material weakness in internal controls over financial reporting related to insufficient resources in the finance function. Management determined this weakness was remediated in 2025.
- Manufacturing Reliance: The company relies exclusively on GeneFab for clinical manufacturing. Disruptions at GeneFab could materially delay clinical trials.
Outlook
The company expects to continue incurring significant losses as it advances SENTI-202 through clinical development. Future capital requirements depend on the progress of clinical trials, regulatory approvals, and the ability to secure additional funding through equity offerings, debt, or collaborations.
Key Facts for Investor Verification
- Liquidity Runway: Verify the company's ability to raise capital before Q2 2026 to avoid operational disruption.
- GeneFab Settlement: Confirm the execution and terms of the March 2026 lease amendments and the reliability of GeneFab's prepaid manufacturing credits as a substitute for cash rent.
- SENTI-202 Clinical Data: Monitor upcoming data readouts from the Phase 1 trial, specifically regarding safety, durability of response, and the performance of the "NOT Gate" logic in sparing healthy cells.
- Manufacturing Capacity: Assess GeneFab's ability to scale manufacturing for SENTI-202 given its lack of prior cGMP facility operation experience.
- Regulatory Status: Track the status of the RMAT designation and any potential interactions with the FDA regarding the path to pivotal trials.